Morgan Stanley expects Novo Nordisk Alzheimer trial to fail as it slashes rating

by | Sep 29, 2025 | Stock Market

Morgan Stanley analysts say a trial to test whether Novo Nordisk’s blockbuster weight-loss drug also will work against Alzheimer’s is likely to fail, as it set the most pessimistic target price forecast of any Wall Street bank on the Danish drugmaker.

Article Attribution | Read More at Article Source